NP43226 Nitric Oxide Therapy
In plain English
The notice doesn't say
Who holds it now
Last won by Merck Sharp & Dohme UK Ltd and Aventis Pharma Ltd Trading As Sanofi and Crescent Pharma Limited and 23 more in Sep 2026, for £61.8m.
- NP49426a Transition MedicinesMerck Sharp & Dohme UK Ltd, Aventis Pharma Ltd Trading As Sanofi, Crescent Pharma Limited and 23 more £61.8m
- NP90726m Vedolizumab (Entyvio®)Takeda UK Limited
- HIV MedicinesAmarox Limited, Glenmark Pharmaceuticals Europe Ltd, Lupin Healthcare UK Ltd and 11 more £89.9m
What you're up against
- The last two awards went to different firms: this buyer has changed supplier before.
- 35 different firms won this buyer's 3 awards for this kind of work in 2026.
- It last went for £61.8m in 2026.
- The last award named 26 suppliers: it may be a framework, where many firms are chosen.
The notice as published
Supply of Nitric Oxide Therapy to NHS Scotland. Supply of Nitric Oxide Therapy to NHS Scotland. The Authority intends to award the Framework Agreement as an unranked multi-supplier framework agreement to a maximum of four (4) Framework Participants. Full details of Goods and volumes can be found within the ITT (Invitation to Tender) documents.